-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In COVID-19 pandemic a year after respiratory syndrome coronavirus 2 (SARS-CoV-2) diseases caused almost no marks on the earth by the severe acute, as of August 9, 2021, 220 countries There are more than 202 million confirmed cases and 4.
28 million deaths in the region
.
The spectrum of diseases ranges from asymptomatic cases with or without mild respiratory symptoms to severe cases with respiratory failure and multiple organ dysfunction
.
In the past year, reports of neurological manifestations related to COVID-19 have increased rapidly, affecting the central nervous system, peripheral nervous system, and musculoskeletal system
The previous systematic review emphasized the frequency of common neurological symptoms observed in COVID-19, including fatigue, myalgia, impaired sense of smell or taste, and headache
.
Other reported neurological manifestations include dizziness, acute confusion/delirium, agitation, stroke, hypoxic-ischemic injury,Epileptic seizures, coma and encephalitis, and so on
epilepsy
In this way, Shubham Misra and others of the All India Institute of Medical Sciences in India conducted a systematic review and meta-analysis to obtain aggregate prevalence estimates and understand the various neurological manifestations of COVID-19 patients in different age groups ( Including symptoms and diagnosis ) report frequency changes
.
This review updates the results of previously published systematic reviews on neurological symptoms , explores the reasons for the heterogeneity of published studies, and provides new insights into the collective prevalence of neurological diagnoses in COVID-19 patients
.
.
They searched PubMed, Medline, Cochrane Library, clinicaltrials.
gov, and EMBASE from December 31, 2019 to December 15, 2020, looking for consecutively enrolled COVID-19 patients with neurological manifestations
Stroke is the most common neurological diagnosis (collective prevalence -2%)
.
Among COVID-19 patients aged ≥60 years, the combined prevalence of acute confusion/delirium was 34%, and any neurological manifestations in this age group were associated with death (OR 1.
80; 95% CI 1.
11 to 2.
91)
Among the COVID-19 patients analyzed in this review, up to one-third have at least one neurological manifestation
.
One out of every 50 patients has experienced a stroke
Among the COVID-19 patients analyzed in this review, up to one-third have at least one neurological manifestation
Original source:
Misra S, Kolappa K, Prasad M, et al.
Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis.
Neurology.
Published online October 11, 2021:10.
Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis.
Neurology.
Published online October 11, 2021:10.
1212/WNL.
Leave a message here
